Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
2 hedge funds and large institutions have $10.2M invested in Seelos Therapeutics, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
1,900% more call options, than puts
Call options by funds: $60K | Put options by funds: $3K
9% more capital invested
Capital invested by funds: $9.4M → $10.2M (+$808K)
0% more funds holding
Funds holding: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$8.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$15K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$12K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $6K | – | – | – |
|
27
Simplex Trading
Chicago,
Illinois
| $4K | – | – | – |
|
|
AIG
28
American International Group
New York
| $3K | – | – | – |
|
29
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $3K | – | – | – |
|
30
BlackRock
New York
| $2K | – | – | – |
|
31
Citigroup
New York
| $1K | – | – | – |
|
|
HDIM
32
Hanson & Doremus Investment Management
Burlington,
Vermont
| $1K | – | – | – |
|
|
ST
33
Sphinx Trading
Chicago,
Illinois
| $1K | – | – | – |
|
34
Geode Capital Management
Boston,
Massachusetts
| $148 | – | – | – |
|
|
35
Citadel Advisors
Miami,
Florida
| – | -$12K | – | – |
|
|
36
Goldman Sachs
New York
| – | -$15K | – | – |
|
SEEL Hedge Fund Activity: Q1 2016 in Review
2 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q1 2016, worth a combined $10.2M — up 8.6% from $9.4M a quarter earlier.
Fund positioning in SEEL was balanced in Q1 2016: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Sarissa Capital Management, adding an estimated $8.6M. The largest seller was Goldman Sachs, cutting an estimated $15K.
- 2 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $10.2M of Seelos Therapeutics, Inc. Common Stock stock for Q1 2016, up 8.6% quarter-over-quarter.
- 0 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q1 2016 and 0 closed out.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q1 2016 was Sarissa Capital Management, an estimated $8.6M added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q1 2016 was Goldman Sachs, an estimated $15K sold.
Based on aggregated 13F filings for Q1 2016.